The substantial increase in the price target for Oncternal Therapeutics by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal to the market, suggesting a higher valuation and potential upside. This is likely to attract investor attention and could lead to a short-term increase in stock price as market participants adjust their expectations based on the new analyst target.